Breaking News

Globalfoundries to Buy IBM's Chip Unit; IBM Sees Pretax Charge $4.7 Billion
Tweet TWEET

Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations

Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations

NEW YORK, Sept. 4, 2013 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc.
(Nasdaq:KERX) today announced that Ron Bentsur, the Company's Chief Executive
Officer, will be presenting at the following upcoming healthcare investor
conferences:

RODMAN & RENSHAW 15^th ANNUAL GLOBAL INVESTMENT CONFERENCE

  *Presentation Date: Monday, September 9, 2013
  *Presentation Time: 10:00am ET

STIFEL NICOLAUS 2013 HEALTHCARE CONFERENCE

  *Presentation Date: Thursday, September 12, 2013
  *Presentation Time: 3:50pm ET

Each of these presentations will be live audio webcast and accessible from the
Investor Information page of the Company's Website at
http://investors.keryx.com. An archived version of each webcast will be
available following the conclusion of the live presentation.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and
commercialization of medically important pharmaceutical products for the
treatment of renal disease. Keryx is developing Zerenex (ferric citrate
coordination complex), an oral, ferric iron-based compound that has the
capacity to bind to phosphate and form non-absorbable complexes. Keryx has
completed a U.S.-based Phase 3 clinical program for Zerenex for the treatment
of hyperphosphatemia (elevated phosphate levels) in patients with chronic
kidney disease on dialysis, conducted pursuant to a Special Protocol
Assessment (SPA) agreement with the Food and Drug Administration (FDA), and
the Company has submitted a New Drug Application to the FDA. The Marketing
Authorization Application filing with the European Medicines Agency (EMA) is
pending submission. Zerenex is also in Phase 2 development in the U.S. for the
management of phosphorus and iron deficiency in anemic patients with Stages 3
to 5 non-dialysis dependent chronic kidney disease. In addition, Keryx's
Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. has
filed its New Drug Application for marketing approval of ferric citrate in
Japan for the treatment of hyperphosphatemia in patients with chronic kidney
disease. Keryx is headquartered in New York City.

CONTACT: KERYX CONTACT:
         Lauren Fischer
         Director - Investor Relations
         Keryx Biopharmaceuticals, Inc.
         Tel: 212.531.5965
         E-mail: lfischer@keryx.com

Keryx Logo
 
Press spacebar to pause and continue. Press esc to stop.